Although Ribeiro's research into kidney fat is too new to have borne results, his earlier work on prostate cancer could hold some clues about the kidney -
cancer obesity paradox.
Not exact matches
To understand the
obesity paradox in kidney
cancer, some researchers are now homing in on the fat that surrounds the kidneys.
Determining whether the
obesity paradox is valid in kidney
cancer matters for clinicians who treat and manage the disease.
That counter-intuitive finding added to a growing body of evidence for an
obesity paradox in kidney
cancer.
When Hakimi, Furberg and colleagues started researching the
obesity paradox in kidney
cancer, they looked into all the ways that their approach might skew the results.
Most people studying the
obesity paradox in kidney
cancer think that changing medical guidelines to endorse
obesity or weight gain rather than weight reduction is misguided.
This would suggest that fat offers no survival advantage — and that the
obesity paradox does not exist in prostate
cancer.
Rather than ratchet up the competition, the various players investigating the
obesity paradox in kidney
cancer did something unusual in the cutthroat world of scientific research: they decided to collaborate.
But critics of the
obesity paradox see that single BMI measurement as problematic, especially when it comes to
cancer.
On the other side of the world, Furberg and kidney specialist Ari Hakimi, also at the Memorial Sloan Kettering
Cancer Center, came across the
obesity paradox in their research.
While
obesity increases the risk of many types of
cancer, it has been suggested that higher BMI decreases mortality risk in
cancer patients, a phenomenon called the «
obesity paradox.»